Intravitreal anti-VEGF therapies for macular edema folowing age-related macular degeneration

Intravitreal anti-VEGF therapies for macular edema folowing age-related macular degeneration - Intravitreal anti-VEGF therapy for AMD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023676

Enrollment

550

Registered

2016-09-01

Start date

2016-11-14

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patinets with age-related macular degeneration

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
visual acuity	—

Secondary

Measure	Time frame
intraocular pressure, central retinal thickness, subfoveal choroidal thickness, nAMD subtype, drusen subtype, recurrence of macular edema, smoking history, medical history (high blood pressure, diabetes, cerebral infarction, myocardial infarction), Plasma catecholamines level	—

Countries

Japan

Contacts

Public ContactHiroyuki Kamao

Kawasaki Medical School Department of Ophthalmology

hironeri@med.kawasaki-m.ac.jp086-462-1111

Outcome results